Tocilizumab in COVID‐19 interstitial pneumonia

BACKGROUND: Published reports on tocilizumab in COVID‐19 pneumonitis show conflicting results due to weak designs or heterogeneity in critical methodological issues. METHODS: This open‐label trial, structured according to Simon's optimal design, aims to identify factors predicting which patient...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Intern Med
Main Authors: Pomponio, G., Ferrarini, A., Bonifazi, M., Moretti, M., Salvi, A., Giacometti, A., Tavio, M., Titolo, G., Morbidoni, L., Frausini, G., Onesta, M., Amico, D., Rocchi, M. L. B., Menzo, S., Zuccatosta, L., Mei, F., Menditto, V., Svegliati, S., Donati, A., D'Errico, M. M., Pavani, M., Gabrielli, A.
格式: Artigo
語言:Inglês
出版: John Wiley and Sons Inc. 2021
主題:
Brief Report
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013903/
https://ncbi.nlm.nih.gov/pubmed/33511686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/joim.13231
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍